Status:
COMPLETED
Study of AK156 in Primary Osteoporosis Patients
Lead Sponsor:
Asahi Kasei Pharma Corporation
Conditions:
Osteoporosis
Eligibility:
All Genders
65-89 years
Phase:
PHASE3
Brief Summary
The purpose of this study is to investigate the efficacy and safety of AK156 in Japanese patients with primary osteoporosis.
Eligibility Criteria
Inclusion
- Patients diagnosed with primary osteoporosis
- Patients who have vertebral fractures at the time of screening
Exclusion
- Patients diagnosed with secondary osteoporosis
- Patients with a current uncontrolled medical disorder or other condition which makes the patient unsuitable for the study
Key Trial Info
Start Date :
February 1 2012
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
January 1 2015
Estimated Enrollment :
600 Patients enrolled
Trial Details
Trial ID
NCT01522521
Start Date
February 1 2012
End Date
January 1 2015
Last Update
October 2 2015
Active Locations (20)
Enter a location and click search to find clinical trials sorted by distance.
1
Chiba, Chiba, Japan
2
Fukuoka, Fukuoka, Japan
3
Kure, Hiroshima, Japan
4
Sapporo, Hokkaido, Japan